This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Generic Drug Stocks to Watch Amid Inflation Pressures
by Sundeep Ganoria
The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.
Amphastar Pharmaceuticals (AMPH) Q3 Earnings Meet Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 0% and 4.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amphastar Pharmaceuticals (AMPH) Q3 Earnings Expected to Decline
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Select Medical (SEM) Plans 3rd Hospital in Central Pennsylvania
by Zacks Equity Research
Select Medical (SEM) joins forces with UPMC to open its third inpatient rehabilitation hospital in Central Pennsylvania to better address the region's post-acute care needs.
Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Haemonetics (HAE) have performed compared to their sector so far this year.
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 5.41% and 4.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 11.96% and 146.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Amphastar Pharmaceuticals (AMPH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 42.42% and 8.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Amphastar Pharmaceuticals (AMPH) This Earnings Season?
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
by Indrajit Bandyopadhyay
The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Amphastar (AMPH) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amphastar Pharmaceuticals (AMPH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 10.53% and 8.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Amphastar Pharmaceuticals (AMPH) a Suitable Value Pick Now?
by Zacks Equity Research
Let's see if Amphastar Pharmaceuticals, Inc. (AMPH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals
3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure
by Indrajit Bandyopadhyay
The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.
Has AmerisourceBergen (ABC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AmerisourceBergen (ABC) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Sail Through the Choppy Market With These 3 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. Amphastar (AMPH), Sanderson Farms (SAFM) and Sensus Healthcare (SRTS) are well poised to gain.
Why You Shouldn't Bet Against Amphastar Pharmaceuticals (AMPH) Stock
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Bet on These 3 Low-Beta Stocks to Combat Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Amphastar Pharmaceuticals (AMPH), AMN Healthcare (AMN) & Sensus Healthcare (SRTS) are well poised to gain.
Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 109.09% and 8.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure
by Zacks Equity Research
The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.